How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,098 results for

E/M Established Outpatient Visit

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Asymptomatic Bacteriuria

: 2019 Update by the Infectious Diseases Society of America a Lindsay E. Nicolle, 1 Kalpana Gupta, 2 Suzanne F. Bradley, 3 Richard Colgan, 4 Gregory P . DeMuri, 5 Dimitri Drekonja, 6 Linda O. Eckert, 7 Suzanne E. Geerlings, 8 Béla Köves, 9 Thomas M. Hooton, 10 Manisha Juthani-Mehta, 11 Shandra L. Knight, 12 Sanjay Saint, 13 Anthony J. Schaeffer, 14 Barbara Trautner, 15 Bjorn Wullt, 16 and Reed Siemieniuk 17 1 Department of Internal Medicine, School of Medicine, Rady Faculty of Health Sciences (...) transplant recipients followed for 1 year after transplant, with urine routinely screened with culture every 3 days for the first 2 weeks, weekly to 1 month, and at each outpatient follow-up visit, reported that 53% of subjects had at least 1 positive urine culture; 53% of the bacteriuric epi- sodes were considered asymptomatic, and 40% of patients had at least 1 episode of ASB [112]. More than one-half of positive cultures were identified in the first month after transplantation, when screening was most

2019 Infectious Diseases Society of America

142. Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection

4.0 Licence. This allows for the copy and redistribution of this document as long as Healthcare Improvement Scotland is fully acknowledged and given credit. The material must not be remixed, transformed or built upon in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nyc- nd/4.0/ www.healthcareimprovementscotland.org SHTG Evidence Synthesis | 20 References 1. Fung M, Kim J, Marty FM, Schwarzinger M, Koo S. Meta-analysis and cost comparison of empirical versus (...) . 2016;8:275-85. 23. Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, et al. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised atients. Clin Ther. 2015;37(6):1317-28. 24. Macesic N, Morrissey CO, Liew D, Bohensky MA, Chen SC, Gilroy NM, et al. Is a biomarker- based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients? Med Mycol. 2017;55(7):705-12.

2019 SHTG Advice Statements

143. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

authority established to promote safety and quality in the provision of health and social care services for the benefit of the health and welfare of the public. HIQA’s mandate to date extends across a wide range of public, private and voluntary sector services. Reporting to the Minister for Health and engaging with the Minister for Children and Youth Affairs, HIQA has responsibility for the following: ? Setting standards for health and social care services — Developing person-centred standards (...) to identify potentially eligible studies. Full text articles were obtained for all citations identified as potentially relevant for inclusion. Both reviewers independently inspected these to establish the relevance of the articles according to the pre-specified criteria. Studies were reviewed for relevance based on study design, types of participants, interventions and outcome measures (see Table 4.1). 4.2.4 Data extraction and management Data were independently extracted using an agreed data extraction

2019 Health Information and Quality Authority

144. HTA of C-reactive protein point-of-care testing to guide antibiotic prescribing

Information and Quality Authority iii About the Health Information and Quality Authority (HIQA) The Health Information and Quality Authority (HIQA) is an independent statutory authority established to promote safety and quality in the provision of health and social care services for the benefit of the health and welfare of the public. HIQA’s mandate to date extends across a wide range of public, private and voluntary sector services. Reporting to the Minister for Health and engaging with the Minister (...) - of-care test with evidence for patients with symptoms of acute respiratory tract infection applicable to the primary care setting. The HTA aimed to establish the clinical and cost-effectiveness of CRP POCT. The HTA also examined the organisational implications of the potential introduction of the technology in primary care. The key findings of this HTA, which informed HIQA’s advice, are: ? Respiratory tract infections (RTIs) are the most frequent infections encountered in primary care, accounting

2019 Health Information and Quality Authority

145. A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: A Canadian analysis

Policy, Management and Evaluation, University of Toronto, Toronto, Canada John Marshall, MD, MSc Professor and Director of the Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Myla E. Moretti, MSc, PhD Senior Research Associate, Ontario Child Health Support Unit and the Clinical Trials Unit, The Hospital for Sick Children, Toronto, Ontario, Canada Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto (...) 17 - Administration Costs 77 Table 18 – Immunosuppressive & Steroid Treatment Cost 78 Table 19 - ICD-10 Codes for Crohn's Disease Costs (OCCI 2015/16) 78 Table 20 - Average Surgical Cost Resection & Length of Stay 79 10 Table 21 - Average Surgical Length of Stay 79 Table 22 - Surgical Procedure Fee 79 Table 23 - Surgical Consultations 80 Table 24 - Post Surgical General Surgery Fees 80 Table 25- Ontario Schedule of Benefits: Surgical and Physician Visit Costs 80 Table 26 - Physician Visits 81

2019 SickKids Reports

146. The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-alpha treatments in pediatric Crohn's disease

Staff Physician, Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada Anne M. Griffiths, MD Staff Physician, Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada Shinya Ito, MD Head, Division of Clinical Pharmacology & Toxicology, The Hospital for Sick Children, Toronto, Canada Professor, Faculty of Medicine, The University of Toronto, Toronto, Canada Wendy J. Ungar, MSc, PhD Senior Scientist, Child Health Evaluative (...) vi 2.1 Overview of Methods and Study Design 27 2.2 The Pediatric Crohn’s Disease Cohort 29 2.2.1 The RISK-PROKIIDS Study Data 29 2.2.1.1 Inclusion Criteria 30 2.2.2 Data Extraction and Patient Characteristics from the RISK-PROKIIDS Study 32 2.2.2.1 Assigning Visit Dates 32 2.2.2.2 Determining Patient Health State 34 2.2.2.2.1 The Weighted Pediatric Crohn’s Disease Activity Index and the Physician Global Assessment 35 2.2.2.3 Treatment Determination 38 2.2.2.4 Extracting Patient Characteristics

2019 SickKids Reports

147. The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)

consumption correlates with in- creased antibiotic resistance, with countries that have moderate to high consumption of antibiotics also having high levels of AMR. However, a causal link between antibiotic consumption and re- sistance is difficult to establish. (A0002) At the patient level, there is a clear link between antibiotic dose and duration and the emergence of antibiotic resistance. There is also evidence that patients who have been treated frequently with antibiotics are at greater risk (...) not generally recommend the use of antibiotics in acute sinusitis, it is unclear what the aim of CRP testing, on its own or as part of a clinical prediction rule, would be even if a suitable threshold could be established. In pharyngitis/tonsillitis, treatment with antibiotics is generally only recommended in those with group A streptococcal (GAS) infection (5% to 30% of those presenting with sore throat). A cut-point of 35 mg/L CRP may be useful in discriminating bacterial from non-bacterial pharyngitis

2019 EUnetHTA

148. Bioresorbable Stents in cardiovascular indications (coronary artery disease)

hospitalisation or outpatient visits [7]. Therefore, revascularisation should ideally prolong life expectancy, reduce symptoms and future revascularisations, and increase health-related quality of life. Safety: Adverse events (AEs) • vascular access site complication • procedure-related contrast-induced nephropathy Bioresorbable stents for cardiovascular indications Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 19 SAEs • late/very late (after =1 year) ScT and/or stent thrombosis and its (...) (studies) Quality Comments Risk with DES or other revascularisation strategies Risk with DESolve ® Scaffold System Effectiveness All-cause mortality — — — — — Outcome not reported Cardiac mortality — — — — — Outcome not reported MI — — — — — Outcome not reported Safety Periprocedural mortality — — — 345 ??? ? very low 5 No events of periprocedural mortality occurred in three single-arm observational studies of the DESolve ® Scaffold System Periprocedural MI — — — 345 ??? ? very low e One periprocedural

2019 EUnetHTA

149. Telehealth for Acute and Chronic Care Consultations

confidence are that inpatient telehealth consultations may reduce length of stay and costs; telehealth consultations in emergency care may improve outcomes and reduce costs due to fewer transfers, and also may reduce outpatient visits and costs due to less travel (low strength of evidence in favor of telehealth). Current evidence shows no difference in clinical outcomes with inpatient telehealth specialty consultations, no difference in mortality but also no difference in harms with telestroke (...) , OR Investigators: Annette M. Totten, Ph.D. Ryan N. Hansen, Pharm.D., Ph.D. Jesse Wagner, M.A. Lucy Stillman, B.S. Ilya Ivlev, M.D., Ph.D., M.B.I. Cynthia Davis-O’Reilly, B.S. Cara Towle, R.N., M.S.N., M.A. Jennifer M. Erickson, D.O. Deniz Erten-Lyons, M.D. Rongwei Fu, Ph.D. Jesse Fann, M.D., M.P.H. Joseph B. Babigumira, M.B.Ch.B., M.S., Ph.D. Katherine J. Palm-Cruz, M.D. Marc Avery, M.D. Marian S. McDonagh, Pharm.D. AHRQ Publication No. 19-EHC012-EF April 2019ii Key Messages Purpose of Review To assess

2019 Effective Health Care Program (AHRQ)

150. Management of Infertility

. Suggested citation: Myers ER, Eaton JL, McElligott KA, Moorman PG, Chatterjee R, Zakama AK, Goldstein K, Strauss J, Coeytaux RR, Goode A, Borre E, Swamy GK, McBroom AJ, Lallinger K, Schmidt R, Davis JK, Hasselblad V, Sanders GD. Management of Infertility. Comparative Effectiveness Review No. 217. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2015-00004-I.) AHRQ Publication No. 19-EHC014-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2019. Posted final (...) EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm. AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the healthcare system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the website (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products

2019 Effective Health Care Program (AHRQ)

151. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00008-I Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Howard A. Fink, M.D., M.P.H. Roderick MacDonald, M.S. Mary L. Forte, Ph.D., D.C. Christina E. Rosebush, M.P.H. Kristine E. Ensrud, M.D., M.P.H. John T. Schousboe, M.D., Ph.D. Victoria A. Nelson, M.Sc. Kristen Ullman, M.P.H. Mary Butler, Ph.D., M.B.A. Carin M. Olson, M.D. Brent C. Taylor, M.P.H., Ph.D. Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S (...) website at www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, Nelson VA, Ullman K, Butler M, Olson CM, Taylor BC, Brasure M, Wilt TJ. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Comparative Effectiveness

2019 Effective Health Care Program (AHRQ)

152. Guidelines for the Economic Evaluation of Health Technologies in Ireland

) is an independent authority established to drive high-quality and safe care for people using our health and social care services in Ireland. HIQA’s role is to develop standards, inspect and review health and social care services and support informed decisions on how services are delivered. HIQA aims to safeguard people and improve the safety and quality of health and social care services across its full range of functions. HIQA’s mandate to date extends across a specified range of public, private and voluntary (...) at SAG meetings as appropriate ? be prepared to occasionally provide expert advice on relevant issues outside of SAG meetings, as requested ? support HIQA in the generation of guidelines to establish quality standards for the conduct of HTA in Ireland ? support HIQA in the development of methodologies for effective HTA in Ireland ? advise HIQA on its proposed HTA Guidelines Work Plan and on priorities as required ? support HIQA in achieving its objectives outlined in the HTA Guidelines Work Plan

2019 Health Information and Quality Authority

153. Treatment of Diabetes in Older Adults

works by this author on: Mark E Molitch Northwestern University Feinberg School of Medicine, Chicago, Illinois Search for other works by this author on: M Hassan Murad Division of Preventive Medicine, Mayo Clinic, Rochester, Minnesota Search for other works by this author on: Alan J Sinclair King’s College, London, United Kingdom Search for other works by this author on: The Journal of Clinical Endocrinology & Metabolism , Volume 104, Issue 5, May 2019, Pages 1520–1574, Published: 23 March 2019 (...) Article history Accepted: 25 January 2019 Received: 25 January 2019 Citation Derek LeRoith, Geert Jan Biessels, Susan S Braithwaite, Felipe F Casanueva, Boris Draznin, Jeffrey B Halter, Irl B Hirsch, Marie E McDonnell, Mark E Molitch, M Hassan Murad, Alan J Sinclair, Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism , Volume 104, Issue 5, May 2019, Pages 1520–1574, Download citation file: © 2019 Oxford University

2019 The Endocrine Society

154. Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (Full text)

, x 41 Maclean, D., Harris, M., Drake, T. et al. Factors predicting a good symptomatic outcome after prostate artery embolisation (PAE). Cardiovasc Intervent Radiol . 2018 ; 41 : 1152–1159 , x 42 Rampoldi, A., Barbosa, F., Secco, S. et al. Prostatic artery embolization as an alternative to indwelling bladder catheterization to manage benign prostatic hyperplasia in poor surgical candidates. Cardiovasc Intervent Radiol . 2017 ; 40 : 530–536 , x 43 Salem, R., Hairston, J., Hohlastos, E. et al (...) techniques. Cardiovasc Intervent Radiol . 2017 ; 40 : 366–374 , x 40 Kurbatov, D., Russo, G.I., Lepetukhin, A. et al. Prostatic artery embolization for prostate volume greater than 80 cm3: results from a single-center prospective study. Urology . 2014 ; 84 : 400–404 , x 41 Maclean, D., Harris, M., Drake, T. et al. Factors predicting a good symptomatic outcome after prostate artery embolisation (PAE). Cardiovasc Intervent Radiol . 2018 ; 41 : 1152–1159 , x 43 Salem, R., Hairston, J., Hohlastos, E. et al

2019 Society of Interventional Radiology

155. Interpregnancy Care

, childhood injuries, and repeated childbearing. A randomized controlled trial. JAMA 1997;278:644–52. El-Kamary SS, Higman SM, Fuddy L, McFarlane E, Sia C, Duggan AK. Hawaii's healthy start home visiting program: determinants and impact of rapid repeat birth. Pediatrics 2004;114:e317–26. Dunlop AL, Dubin C, Raynor BD, Bugg GW Jr, Schmotzer B, Brann AW Jr. Interpregnancy primary care and social support for African-American women at risk for recurrent very-low-birthweight delivery: a pilot evaluation (...) live birth or pregnancy loss and the start of the next pregnancy; specifically, it will focus on this interval after a woman has transitioned from postpartum care. Existing Recommendations The concept of interpregnancy care is well established and multiple organizations have put forth their own distinct set of interpregnancy care recommendations (5, ). However, many of these recommendations are focused solely on improving neonatal outcomes of future pregnancies. This document will focus

2019 American College of Obstetricians and Gynecologists

156. Ethical Considerations for the Care of Patients With Obesity

, and specially designed instruments for use in the operating room. Additionally, surgical procedures that often are performed in more cost-effective outpatient surgical centers may need to be undertaken in hospitals because of increased anesthesia risks to patients with obesity, along with other medical considerations. These surgical procedures may be more complex, and they may be of longer duration. During pregnancy, more frequent ultrasonography may be required to monitor fetal growth and presentation (...) to address any identified bias to help ensure that it does not interfere with the delivery of respectful clinical care for patients with obesity. Box 1 includes questions for self-reflection to help obstetrician–gynecologists identify implicit bias. Patient-Centered Counseling to Address Obesity Obstetrician–gynecologists may find it difficult during a typical office visit to initiate a dialogue about weight, healthy diet, and lifestyle, especially when other problems must be addressed or if the patient

2019 American College of Obstetricians and Gynecologists

157. Clinical Practice Guideline for the Management of Infantile Hemangiomas

. Clinical Practice Guideline for the Management of Infantile Hemangiomas Daniel P. Krowchuk , Ilona J. Frieden , Anthony J. Mancini , David H. Darrow , Francine Blei , Arin K. Greene , Aparna Annam , Cynthia N. Baker , Peter C. Frommelt , Amy Hodak , Brian M. Pate , Janice L. Pelletier , Deborah Sandrock , Stuart T. Weinberg , Mary Anne Whelan , SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS Abstract Infantile hemangiomas (IHs) occur in as many as 5% of infants, making them the most common (...) clinical judgment, or to establish a protocol for all infants with IHs. Rather, it provides a framework for clinical decision-making. Methods The methods of this CPG are discussed in detail in the Methods section of the . Briefly, a comparative effectiveness review of potential benefits and harms of diagnostic modalities and pharmacologic and surgical treatments was conducted on behalf of the Agency for Healthcare Research and Quality (AHRQ). The literature search strategy employed Medline via

2019 American Academy of Pediatrics

158. Syphilis in pregnancy

at risk of congenital syphilis o Identify the most appropriate service as relevant to the local context (e.g. paediatric outpatient clinic or outreach service) o Establish a local process for initiating and ensuring follow-up occurs, including if baby discharged prior to pathology result availability · Use audit processes to monitor and review follow-up care and clinical outcomes Communication · Communicate with the multidisciplinary team—the identified referral pathways and responsibility for follow (...) purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au, phone (07) 3131 6777. For permissions beyond the scope of this licence, contact: Intellectual Property

2019 Queensland Health

159. 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

. Hayden, Scott A. Harper, Jon Mark Hirshon, Michael G. Ison, B. Lynn Johnston, Shandra L. Knight, Allison McGeer, Laura E. Riley, Cameron R. Wolfe, Paul E. Alexander, and Andrew T. Pavia For full document, including tables and references, please visit the . Abstract These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding (...) 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Influenza Search Search Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Published : 19 December 2018 Timothy M. Uyeki, Henry H. Bernstein, John S. Bradley, Janet A. Englund, Thomas M. File Jr, Alicia M. Fry, Stefan Gravenstein, Frederick G

2019 Infectious Diseases Society of America

160. Tobacco Cessation Treatment

. Guidance for Clinicians’ Discussions of E-Cigarettes With Patients.. - 6.9.3. Alternative Tobacco Products: HNB Tobacco - 6.10. Training and Implementation .. - Table 11. Strategies for Addressing Barriers to ImplementingandSustainingSmokingCessation Treatment in the Clinical Setting .. - Table 12. Resources for Educational Information to Support Implementation of Tobacco Dependence Treatment in Clinical Cardiology Settings .. - Table 13. Potential Participants in an Inpatient or Outpatient Smoking (...) , MPH, FACC Barbara S. Wiggins, PHARMD, FACC Task Force on Expert Consensus Decision Pathways James L. Januzzi JR, MD, FACC, Chair Tariq Ahmad, MD, MPH, FACC Brendan Everett, MD, FACC William Hucker, MD, PHD Dharam J. Kumbhani, MD, SM, FACC Joseph E. Marine, MD, FACC Pamela B. Morris, MD, FACC Robert N. Piana, MD, FACC Sunil V. Rao, MD, FACC Marielle Scherrer-Crosbie, MD, PHD Karol E. Watson, MD, FACC Barbara S. Wiggins, PHARMD, AACC TABLE OF CONTENTS PREFACE .. - 1.ABSTRACT - 2.INTRODUCTION . - 3

2019 American College of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>